Moderna and Novavax Rally: ‘Cancer Vaccine’ Stocks Get a Shot of Investor Confidence -( $IBB MRK $MRNA $NVAX $SNY $XBI )

Clinical progress, a proposed U.S. research initiative and vaccine licensing economics strengthen the bull case.

Biotechnology investors are finding fresh reasons to look beyond the pandemic trade. Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX) and Merck (NYSE: MRK) rallied on October 9 as enthusiasm for vaccine innovation intersected with reports of a proposed U.S. initiative to accelerate personalized cancer vaccine development. The opportunity is not identical for each company, but the broader investment theme is becoming more compelling: vaccines are evolving from a public-health necessity into a wider arena for precision medicine, technology licensing and commercial growth. An intraday report carried by Yahoo Finance on Friday showed Novavax advancing approximately 16%, Moderna gaining about 11% and Merck climbing roughly 3%. The same report put the iShares Biotechnology ETF (NASDAQ: IBB) up approximately 3%, compared with a gain of about 0.5% for the SPDR S&P 500 ETF Trust (NYSEARCA: SPY). Those figures represent a market snapshot, not verified closing returns, but the message was clear: biotechnology was attracting attention well beyond the usual defensive-healthcare crowd. Wall Street, it seems, has rediscovered that a laboratory can produce something more interesting than another quarterly slide deck.

Why Moderna Stock Is Attracting Fresh Attention

The most consequential development for Moderna is not simply a stronger appetite for biotech shares. It is the clinical evidence supporting its expansion into oncology. In August, Moderna and Merck announced positive topline results from the Phase 3 INTerpath-001 study of intismeran autogene, an investigational individualized cancer therapy, combined with Merck’s Keytruda, or pembrolizumab. The study evaluated patients with completely resected stage IIB-IV melanoma. Reporting on the results said the combination met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. Those endpoints address two central questions after surgery: how long patients remain free of a recurrence, and how long they remain free of cancer spreading to distant parts of the body. Importantly, Moderna says follow-up continues for other endpoints, including overall survival. Progress on recurrence should not be confused with a demonstrated overall-survival benefit. The investment significance is substantial. A successful oncology program could broaden how investors assess Moderna, shifting the discussion from demand for individual infectious-disease vaccines toward the commercial possibilities of its underlying mRNA platform. That is the bullish interpretation, not a declaration that the commercial outcome is settled. Intismeran remains investigational, and clinical success must still translate into regulatory clearance, reliable manufacturing and adoption by physicians and payers.

Personalized Cancer Vaccines Give mRNA a Larger Stage

The phrase “cancer vaccine” can obscure an important distinction. The personalized therapies at the center of the proposed U.S. initiative are treatments designed to help the immune system recognize and attack a patient’s specific cancer, rather than routine preventive shots given to the general population. Moderna describes its approach as using the unique genetic information in an individual patient’s tumor to design a tailored therapy that helps train the immune system to fight it. The company and Merck are studying intismeran across multiple cancer types and disease settings, including melanoma, lung, bladder and kidney cancers. For many, this creates a potentially valuable relationship between an initial indication and a broader development platform. Success in melanoma does not establish efficacy in another cancer. It does, however, provide a stronger clinical foundation for testing the technology elsewhere. The distinction matters. One promising product can support a business. A reproducible platform can potentially support a portfolio.

A Proposed U.S. Cancer Vaccine Initiative Adds Strategic Momentum

The New York Times reported that a planned public-private partnership would bring together the National Institutes of Health, the Foundation for the NIH, researchers, pharmaceutical and biotechnology companies, advocacy organizations, philanthropies and patients. The initiative was expected to begin in December, initially focusing on pancreatic, liver and colorectal cancers, along with a subset of pediatric tumors. This is potentially meaningful institutional support for the field, but it is not the same as an announced procurement contract or a guaranteed revenue stream for Moderna, Merck or Novavax. The constructive investment interpretation is that coordinated research could improve how personalized cancer vaccines are developed and tested. Companies with established clinical programs may be well positioned to contribute expertise as the field advances. The initiative’s commercial consequences, however, remain uncertain. For Moderna and Merck, the policy discussion arrives alongside an existing late-stage oncology program. That combination gives investors more to evaluate than a compelling scientific concept alone.

Merck Offers a Different Route Into the Cancer Vaccine Opportunity

Merck’s role in the partnership gives investors exposure to personalized cancer therapy through a diversified pharmaceutical company rather than a more concentrated vaccine developer. Keytruda is the established treatment against which the combination is being evaluated. Moderna’s Phase 3 recap states that adding intismeran demonstrated a clinically meaningful improvement over pembrolizumab alone in the studied melanoma population. The strategic attraction is straightforward: a successful combination could expand treatment possibilities around an existing immunotherapy franchise while giving Merck a role in the development of individualized cancer medicine. The companies nonetheless present different investment profiles. Moderna’s oncology progress can have an outsized effect on expectations for its platform. Merck’s broader pharmaceutical business makes the same program one component of a larger enterprise. The October 9 reporting highlighted that distinction when explaining why Merck’s shares moved less sharply than those of the vaccine developers.

Novavax’s Bull Case Runs Through Licensing, Not the Same Oncology Program

Novavax should not be folded into the Moderna-Merck cancer vaccine thesis simply because its shares rallied alongside them. Its investment case centers on protein-based vaccines, its Matrix-M adjuvant technology and partnerships that can generate milestone payments and royalties. The October 9 article identified no fresh company-specific catalyst for Novavax’s rally, describing the move primarily as part of a broader biotechnology and vaccine-sector advance. The underlying licensing opportunity is more concrete. Under the agreement announced in May 2024 with Sanofi (NASDAQ: SNY), Novavax was entitled to a $500 million upfront payment and up to $700 million in additional development, regulatory and launch milestones. The agreement also established tiered double-digit percentage royalties on specified COVID-19 and COVID-19-influenza vaccine sales by Sanofi. These were contractual terms announced at the time, not a statement of cash still available to be collected today. A September 2025 update broadened the partnership to allow early-stage development of Sanofi pandemic influenza vaccine candidates using Matrix-M through Phase 2. Novavax also described additional potential milestone and royalty opportunities for products incorporating its adjuvant. The appeal is a more capital-efficient route to commercialization: Novavax can participate in a larger partner’s development and distribution capabilities without independently carrying every associated expense. The limitation is that milestone revenue arrives unevenly and depends on partner progress. In biotechnology, a royalty stream can be an elegant business model. It still requires someone upstream to turn on the tap.

The Vaccine Growth Story Extends Beyond COVID-19

A Research and Markets report announcement distributed through Yahoo Finance projected that the global vaccine market could grow from approximately $48 billion to $94 billion by 2030. The release cited broader immunization programs, infectious-disease demand, advances in vaccine technology and investment in regional manufacturing as growth drivers. That forecast needs proper context. The source is a paid market-research press release, and its summary does not clearly identify the starting year for the $48 billion estimate. It should therefore be treated as a directional industry forecast, not a precise valuation input or an independently established market outcome. The release nevertheless describes a broader industry shift toward respiratory syncytial virus, influenza, pneumococcal disease, dengue, malaria, human papillomavirus and other targets. It also points to combination vaccines, improved formulations and alternative delivery methods as development priorities. This conventional vaccine-market forecast should not be treated as the addressable market for personalized oncology therapies. They are distinct opportunities with different patients, development requirements and commercial economics. For many, that distinction improves the story rather than weakening it: infectious-disease innovation, oncology development and technology licensing provide separate potential growth engines.

What Could Turn the Rally Into a Durable Investment Thesis?

The next stage requires evidence that strengthens the connection between scientific progress and business value. For Moderna and Merck, detailed melanoma results are an important checkpoint. Barchart’s October 9 report identified October 24 at the ESMO Congress as the scheduled presentation of detailed Phase 3 findings. Many will need to assess the magnitude of benefit, safety findings and implications for the regulatory path. For Novavax, partner development milestones, royalties and execution of its licensing strategy are more relevant than assuming every cancer vaccine headline directly benefits its business. Valuation also remains part of the equation. Barchart’s report cautioned that Moderna’s substantial rally had already raised expectations and described a “Hold” analyst consensus at the time. A stronger company outlook and an attractive entry price are related questions, but they are not interchangeable. The sector’s renewed appeal rests on a credible progression: promising biology, stronger clinical validation and business models capable of capturing the resulting value. Moderna brings personalized mRNA oncology exposure. Merck contributes an established immunotherapy platform and pharmaceutical scale. Novavax offers a different path through protein-based vaccines, adjuvant licensing and partner economics. That is a more substantial investment story than a synchronized jump in three tickers. The rally attracts attention. The science and commercial execution will determine whether it deserves to keep it.

The Sources

1. Barchart, via Yahoo Finance: “Moderna Stock Skyrockets on Reports of U.S. Cancer Vaccine Initiative”
   https://finance.yahoo.com/markets/stocks/articles/moderna-stock-skyrockets-reports-u-191710258.html
2. Yahoo Finance: “Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies”
   https://finance.yahoo.com/healthcare/articles/novavax-soars-16-moderna-surges-175942844.html
3. The New York Times: “Cancer Vaccines Are the NIH’s Next ‘Big Bet’”
   https://www.nytimes.com/2026/10/09/science/cancer-vaccines-nih-big-bet.html
4. Moderna: “Recapping Positive Phase 3 Topline Results for Intismeran Autogene Plus Pembrolizumab”
   https://www.modernatx.com/ir-insights-phase-3-intesmeran
5. Novavax: “Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines”
   https://ir.novavax.com/press-releases/2024-05-10-Novavax-and-Sanofi-Announce-Co-exclusive-Licensing-Agreement-to-Co-commercialize-COVID-19-Vaccine-and-Develop-Novel-COVID-19-Influenza-Combination-Vaccines
6. Novavax: “Novavax Announces Progress on Sanofi Agreement”
   https://ir.novavax.com/press-releases/2025-09-30-Novavax-Announces-Progress-on-Sanofi-Agreement
7. Research and Markets, via Yahoo Finance: “Vaccines Global Market Intelligence Report 2026-2035”
   https://finance.yahoo.com/healthcare/articles/vaccines-global-market-intelligence-report-110200087.html